Squarepoint
RLMD icon

Squarepoint’s Relmada Therapeutics RLMD Stock Holding History

Squarepoint’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-63,426
Closed -$441K – 4893
2026
Q1 		$441K Sell
63,426
-74,807
-54% -$354K ﹤0.01% 3405
2025
Q4 		$668K Buy
+138,233
New +$463K ﹤0.01% 2964
2024
Q3 		– Sell
-35,425
Closed -$106K – 4608
2024
Q2 		$106K Sell
35,425
-43,588
-55% -$158K ﹤0.01% 3786
2024
Q1 		$367K Buy
79,013
+5,579
+8% +$26.9K ﹤0.01% 3256
2023
Q4 		$304K Buy
73,434
+40,337
+122% +$119K ﹤0.01% 3350
2023
Q3 		$99.3K Sell
33,097
-45,923
-58% -$136K ﹤0.01% 3558
2023
Q2 		$194K Buy
+79,020
New +$218K ﹤0.01% 3232
2023
Q1 		– Sell
-35,281
Closed -$123K – 3724
2022
Q4 		$123K Buy
+35,281
New +$310K ﹤0.01% 2931
2021
Q1 		– Sell
-7,130
Closed -$229K – 3533
2020
Q4 		$229K Buy
+7,130
New +$245K ﹤0.01% 2419
2020
Q3 		– Sell
-8,106
Closed -$363K – 2786
2020
Q2 		$363K Buy
+8,106
New +$343K 0.01% 1483
2020
Q1 		– Sell
-8,918
Closed -$348K – 2404
2019
Q4 		$348K Buy
+8,918
New +$271K ﹤0.01% 1965

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Squarepoint's RLMD Position: Q2 2026 in Review

Squarepoint sold out of Relmada Therapeutics (RLMD) in Q2 2026, closing a stake of 63,426 shares — an estimated $441K sold.

Squarepoint first reported a position in RLMD in Q4 2019 and held it in 11 quarters. The position peaked at $668K in Q4 2025. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Squarepoint reported no remaining Relmada Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Squarepoint sold 63,426 Relmada Therapeutics shares in Q2 2026, an estimated $441K.
  • Squarepoint first reported a position in Relmada Therapeutics in Q4 2019 and held it in 11 quarters.
  • Squarepoint's Relmada Therapeutics position peaked at $668K in Q4 2025.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.